How to appeal a Humana myasthenia gravis & cidp denial

The framework that applies to your appeal

Medicare Advantage plans follow a separate appeal track from commercial plans. Reconsideration must be requested within 60 days; if the plan misses its deadline, the case auto-forwards to the IRE (Maximus).

Humana-specific note: Heavily Medicare Advantage focused. MA-specific appeal track (42 CFR Part 422 Subpart M) applies — 60 days to request reconsideration, NOT the 180 days for commercial plans. Auto-forward to IRE (Maximus) if Humana misses deadline.

What Humana's policy requires for myasthenia gravis & cidp

Cited policy: Humana Hizentra (Immune Globulin Subcutaneous) for CIDP Maintenance

Diagnosis of CIDP per EAN/PNS 2021 criteria. Prior documented response to IV IVIG (improvement in INCAT or I-RODS). Transition to home SCIG for maintenance after IV IVIG induction/stabilization. Weekly self-administered SCIG dosing per Hizentra CIDP label. Reauth at 12 mo with maintained disability scoring.

How Humana denies myasthenia gravis & cidp — and how to counter it

Where Humana pushes back: 1) Continue IV IVIG infusions — SCIG not necessary; 2) SCIG more expensive per-dose than IVIG; 3) Self-administration not appropriate.

Counter-arguments that hold up: Hizentra FDA-approved Mar 16, 2018 for CIDP maintenance after IVIG response — only FDA-approved SCIG for CIDP. PATH trial (Mielke Lancet Neurol 2018) — Phase 3 SCIG vs placebo in CIDP maintenance; significant reduction in CIDP relapse, supported FDA label expansion. Home SCIG eliminates wear-off effect (smoother IgG troughs), reduces hospital infusion-chair burden, eliminates venous-access morbidity, improves patient-reported outcomes and QoL. EAN/PNS 2021 endorses SCIG as maintenance equivalent to IVIG. Patient choice + caregiver availability + travel burden support transition. Cost comparison should include infusion-chair facility fees + lost workdays + venous-access procedures.

What Humana typically denies for myasthenia gravis & cidp

Across Humana's commercial and Medicare books, denials cluster around a small number of patterns. For myasthenia gravis & cidp, expect:

• MA plan step therapy on Part B drugs
• Skilled nursing facility days
• Prior auth on specialty drugs
• OON emergency reduction

Treatments most often denied in this category

These are the myasthenia gravis & cidp treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Soliris (MG)
• Ultomiris (MG)
• Vyvgart IV (MG)
• Vyvgart Hytrulo (MG)
• Rystiggo (MG)
• Zilbrysq (MG)

How to submit the appeal to Humana

1. Read the denial letter — note the exact denial reason code and the appeal deadline (60 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Humana cited in the denial.
3. File the appeal through Humana's portal (members: https://www.humana.com ; providers: https://www.humana.com/provider). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In KY, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Humana's prior-authorization criteria by drug: Humana PA criteria on ApprovalHelp.